Journal «Angiology and Vascular Surgery» • 

2015 • VOLUME 21 • №4

Results of comprehensive treatment of patients with chronic lower limb ischaemia using gene-engineering technologies of angiogenesis stimulation (Part 2)

Gavrilenko A.V.1,2, Voronov D.A.1,2

1) Vascular Surgery Department, Russian Research Centre of Surgery named after Academician B.V. Petrovsky under the Russian Academy of Medical Sciences, Moscow, Russia
2) Chair of Cardiovascular Surgery No1 named after B.V. Petrovsky, Institute of Professional Education of the First Moscow State Medical University named after I.M. Sechenov, Moscow, Russia

Presented herein are the results of clinical use of gene engineering methods of stimulating angiogenesis in patients with lower limb chronic ischaemia. An open prospective controlled clinical study included a total of 160 patients with lower limb chronic ischaemia. Gene engineering technologies of angiogenesis stimulation were used both as an independent method of treatment in comprehensive conservative therapy (80 patients) and as comprehensive treatment in combination with revascularizing operations (80 patients). Part Two of the article deals with the results of using the above technologies in the composition of comprehensive treatment.

It was shown that gene-engineering technologies of angiogenesis stimulation may successfully be used in comprehensive conservative treatment in patients with stage IIB CLLI, as well as stage III. Clinically meaningful improvement is confirmed by objective factors, including better parameters of regional haemodynamics, perfusion, functional reserve of blood flow, etc.

Gene-engineering methods of angiogenesis stimulation were found demonstrated were associated with good tolerance and an admissible rate of adverse events in patients with CLLI. All undesirable events turned out transitory during the immediate follow-up period.

KEY WORDS: chronic lower limb ischaemia, surgical management, pharmacotherapy, comprehensive treatment, angiogenesis, angiogenesis stimulation, gene-engineering therapy, vascular endothelial growth factor, angiogenin.

P. 35

« Back